Cefepime

Cefepime

Clinical data
Pregnancy category	B1 (Au)
Routes of administration	Intravenous, intramuscular
ATC code	J01DE01 (WHO)
Legal status
Legal status	S4 (Au)
Pharmacokinetic data
Bioavailability	100% (IM)
Metabolism	Hepatic 15%
Elimination half-life	2 hours
Excretion	Renal 70–99%
Identifiers
IUPAC name (6R,7R,Z)- 7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)- 3-((1-methylpyrrolidinium-1-yl)methyl)-8-oxo-5-thia- 1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate
CAS Number	88040-23-7
PubChem CID	68606
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H24N6O5S2
Molar mass	480.56 g/mol

WikiDoc Resources for Cefepime
Articles
Most recent articles on Cefepime Most cited articles on Cefepime Review articles on Cefepime Articles on Cefepime in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefepime Images of Cefepime Photos of Cefepime Podcasts & MP3s on Cefepime Videos on Cefepime
Evidence Based Medicine
Cochrane Collaboration on Cefepime Bandolier on Cefepime TRIP on Cefepime
Clinical Trials
Ongoing Trials on Cefepime at Clinical Trials.gov Trial results on Cefepime Clinical Trials on Cefepime at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefepime NICE Guidance on Cefepime NHS PRODIGY Guidance FDA on Cefepime CDC on Cefepime
Books
Books on Cefepime
News
Cefepime in the news Be alerted to news on Cefepime News trends on Cefepime
Commentary
Blogs on Cefepime
Definitions
Definitions of Cefepime
Patient Resources / Community
Patient resources on Cefepime Discussion groups on Cefepime Patient Handouts on Cefepime Directions to Hospitals Treating Cefepime Risk calculators and risk factors for Cefepime
Healthcare Provider Resources
Symptoms of Cefepime Causes & Risk Factors for Cefepime Diagnostic studies for Cefepime Treatment of Cefepime
Continuing Medical Education (CME)
CME Programs on Cefepime
International
Cefepime en Espanol Cefepime en Francais
Business
Cefepime in the Marketplace Patents on Cefepime
Experimental / Informatics
List of terms related to Cefepime

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Cefepime (INN) (IPA: Template:IPA) is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents. Cefepime hydrochloride was first marketed in 1994 and is currently marketed under various trade names including Maxipime (Elan Pharma), Maxcef, Cepimax, Cepimex, and Axepim.

Clinical use

Main article: Cephalosporin

Cefepime is usually reserved to treat severe nosocomial pneumonia, infections caused by multi-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia. The use of cefepime might become less common, since it has been associated to an increase mortality when used for different types of infections.

Cefepime has good activity against important pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, and multiple drug resistant Streptococcus pneumoniae. A particular strength is its activity against Enterobacteriaceae. Whereas other cephalosporins are degraded by many plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and is a front line agent when infection with Enterobacteriaceae is known or suspected.

Chemistry

The combination of the syn-configuration of the methoxyimino moiety and the aminothiazolyl moiety confers extra stability to β-lactamase enzymes produced by many bacteria. The N-methylpyrrolidine moiety increases penetration into Gram-negative bacteria. These factors increases the activity of cefepime against otherwise resistant organisms including Pseudomonas aeruginosa and Staphylococcus aureus.

References

^ Chapman TM, Perry CM. Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am JRespir Med. 2003;2(1):75-107. PMID 14720024 ^ Yahav, D et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet 2007; 7:338-348.

See also

• Cephalosporin

External links

• Maxipime fact sheet – Elan Pharmaceuticals